Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet
Pressmeddelande

Analyst Group: Equity Research Report on Pharma Equity Group - Strengthened Balance Sheet Facilitates Continued Development

Pharma Equity Group

Following the end of Q3-24, Pharma Equity Group (“PEG” or “the Company”) secured additional funding through a directed share issue, with a significant portion allocated to debt reduction. This strengthens the Company’s financial position, providing increased flexibility to advance the development of PEG’s drug candidates while enhancing the Company’s negotiating leverage with potential licensing partners. Furthermore, PEG recently obtained patent protection in Japan, a key future market, for the treatment of colorectal cancer with RNX-051, valid until 2039. Following a reassessment of market conditions, an updated royalty rate has been applied, resulting in a potential present market value of DKK 950m, corresponding to DKK 0.8 (1.2) per share in a Base scenario.


Read the equity research report here


About Analyst Group: One of Sweden's fastest growing equity research boutiques with a focus on small and medium-sized listed companies.
Read more about Analyst Group (Swedish)

This is a press release from Analyst Group regarding the publication of an analysis on Pharma Equity Group. Readers may assume that Analyst Group has received compensation for making the commentary. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Our team
  • Careers
  • Inderes som en investering
  • Tjänster för börsbolag
Our platform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet